Welcome to Industry Focus, the show that dives into a different sector of the stock market every single day.

Today is Wednesday, April the 10th, and we're talking health care.

I'm your host Shannon Jones. I am joined via Skype by

health care guru Todd Campbell. Todd how are you? Hi Shannon how are you doing

today? I am doing well thanks I'm super excited for today's show where I diving into one of the

hottest areas in terms of investments in the bio-pharma space that's none other

than the gene.

So we're going to kick things off talking a little bit about the latest billion dollar partnership deal.

And then we'll be serving up three top genomic stocks that every listener should at least be watching

if not adding to your portfolio. Todd, let's just kick things right off from the beginning.

This billion dollar partnership

deal really not necessarily a new deal I would consider it more strengthening a

deal between two massive players in the space first off al-N-L-N-L Pharmaceuticals that sticker symbol A.L. and Y.

Best known for their gene silencing platform, which we'll talk a little bit more about.

But they announced they'd be strengthening their

partnership one of them with one of the most profitable drug makers in the

S&P 500 that's Regeneron ticker symbol R E, G, N. Todd, interestingly enough, analysts actually seemed to like the deal.

Seems to make sense for both. But the market wasn't necessarily cheering for this deal.

Immediately after the news came out.

Nialum was down about 3%, Regeneron down about 2%.

Todd, what's the deal with this deal?

Yeah, it's a big collective yawn by Wall Street investors on the deal, despite the

...